Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
STLN Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Starling Oncology, Inc.
Market Cap
$657.89M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$656.59M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$660.29M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
Market Cap
$666.95M
Return on Equity (ROE)
-75.79%
TTM Avg
-55.51%
3Y Avg
-59.06%
5Y Avg
-60.41%
Market Cap
$673.41M
Return on Equity (ROE)
2.89%
TTM Avg
20.45%
3Y Avg
11.91%
5Y Avg
-3.26%
Market Cap
$638.20M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$681.02M
Return on Equity (ROE)
-405.51%
TTM Avg
42.95%
3Y Avg
-55.53%
5Y Avg
-60.37%
Market Cap
$681.27M
Return on Equity (ROE)
-55.36%
TTM Avg
-93.85%
3Y Avg
-76.06%
5Y Avg
-67.62%
Market Cap
$634.30M
Return on Equity (ROE)
26.77%
TTM Avg
-106.09%
3Y Avg
-80.56%
5Y Avg
-51.63%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -43.95% | -29.61% | -34.61% | -30.48% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -108.93% | -72.41% | -64.95% | -55.74% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -75.79% | -55.51% | -59.06% | -60.41% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 2.89% | 20.45% | 11.91% | -3.26% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -41.56% | -67.38% | -49.66% | -56.07% |
| Verastem, Inc. (VSTM)vs › | $681.02M | -405.51% | 42.95% | -55.53% | -60.37% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -55.36% | -93.85% | -76.06% | -67.62% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 26.77% | -106.09% | -80.56% | -51.63% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -471.98% | -147.16% | -120.43% | -93.49% |
ROE
N/A
ROA
-20.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 385.53% |
